PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20113225-6	2010	RESULTS: IL-1 beta increased GAG release and aggrecanase activity (11-fold).	Glycosaminoglycans	29-32	interleukin-1 beta	Equus caballus	9-18	
29749312-11	2018	IL-1beta mediated suppression of GAG synthesis was not rescued by IL-10.	Glycosaminoglycans	33-36	interleukin-1 beta	Equus caballus	0-8	
25998424-4	2015	Very low levels of oxygen (<1%), acidosis (pH 6.2), and exposure to IL-1beta led to reductions in cell viability, increased GAG release, alterations in DeltaPsim and ROS levels, and reduced GSH:GSSG ratio.	Glycosaminoglycans	127-130	interleukin-1 beta	Equus caballus	71-79	
24373218-15	2013	Overall, during the two time courses, GAG release was 58.67% +- 10.91% (SD) for IL-1beta versus 52.91% +- 9.35% (SD) with carprofen + IL-1beta.	Glycosaminoglycans	38-41	interleukin-1 beta	Equus caballus	80-88	
16740087-7	2006	RESULTS: IL-1beta-induced GAG loss from cartilage was significantly less in cocultures than in cartilage-only cultures.	Glycosaminoglycans	26-29	interleukin-1 beta	Equus caballus	9-17	
16740087-10	2006	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that synoviocytes secrete 1 or more mediators that preferentially protect matrix GAG metabolism from the degradative effects of IL-1beta.	Glycosaminoglycans	133-136	interleukin-1 beta	Equus caballus	180-188	
15727892-6	2005	RESULTS: IL-1beta and LPS stimulated significant release of GAG, NO, PGE2 and MMP-3.	Glycosaminoglycans	60-63	interleukin-1 beta	Equus caballus	9-17	
14974582-8	2004	In cartilage explants conditioned with IL1-beta, IGF-II stimulated DNA and GAG synthesis at concentrations of 500 and 50 ng/mL, respectively.	Glycosaminoglycans	75-78	interleukin-1 beta	Equus caballus	39-47